华东医药：全资子公司收到罗氟司特乳膏上市许可申请受理通知书

Core Viewpoint - Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Sino-American Huadong, received the Acceptance Notice from the National Medical Products Administration for the marketing application of ZORYVE (0.05% Roflumilast Cream), aimed at treating mild to moderate atopic dermatitis in patients aged 2 to 5 years [1] Group 1: Product Development - The drug is a collaborative innovation between Sino-American Huadong and Arcutis Biotherapeutics, Inc., with exclusive rights in Greater China and Southeast Asia [1] - Roflumilast cream offers safety advantages over traditional treatment methods and can be applied to all body parts with once-daily dosing, enhancing treatment adherence [1] Group 2: Market Positioning - The acceptance of the marketing application represents a significant milestone in the product development process, which will enhance the company's core competitiveness in the autoimmune skin treatment sector [1] - There are uncertainties regarding the drug review and approval timeline, approval outcomes, and future market competition dynamics [1]